- Tumors1000+
- Cancer1000+
- Pathologic Processes1000+
- Pathology1000+
- Nervous System Diseases1000+
Any
<10 miles
<30 miles
<50 miles
<70 miles
Filter Results
Condition
- Tumors1000+
- Cancer1000+
- Pathologic Processes1000+
- Pathology1000+
- Nervous System Diseases1000+
Where are you looking?
How far are you willing to travel?Any
How old are you?
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
- HER2 negative
- ER positive
- PD-L1 positive
- HER2 positive
- PR positive
- ER negative
- PR negative
- EGFR positive
- PD-L1 negative
- BRAF positive
- KRAS positive
- EGFR negative
- p16 positive
- BRCA1 positive
- HLA-A positive
- ALK negative
- BRCA2 positive
- CD20 positive
- IDH positive
- MET positive
- ALK positive
- BRAF negative
- HLA positive
- CD19 positive
- MYC positive
- HLA negative
- TP53 positive
- IDH negative
- MSI-H positive
- p16 negative
- HPV positive
- ROS1 negative
- ROS1 positive
- FLT3 positive
- HLA-A negative
- MET negative
- PALB2 positive
- PIK3CA positive
- RB1 positive
- HR positive
- RET positive
- NRAS positive
- RB1 negative
- dMMR positive
- BRCA positive
- BCL2 positive
- HPV negative
- NF1 positive
- RAS positive
- KRAS negative
- BCL6 positive
- CCND1 positive
- NTRK positive
- ATM positive
- BCR-ABL1 positive
- ANA positive
- MSS positive
- TP53 negative
- HbSS positive
- PTEN positive
- BRCA1 negative
- CD5 positive
- MGMT negative
- MSH2 positive
- PD-1 positive
- RAS negative
- RET negative
- anti-dsDNA positive
- ARID1A positive
- BRCA2 negative
- BRIP1 positive
- CHEK2 positive
- FGFR2 positive
- MLH1 positive
- MMR positive
- MSH6 positive
- PMS2 positive
- RAD51 positive
- CD30 positive
- KIT positive
- MMR negative
- MSI negative
- NRAS negative
- ctDNA positive
- CD123 positive
- CD22 positive
- CDK12 positive
- FGFR positive
- MGMT positive
- MSI positive
- PD-1 negative
- dMMR negative
- FANCA positive
- HBV DNA negative
- L858R positive
- NTRK negative
- NTRK1 positive
- Philadelphia Chromosome positive
- RAD51C positive
- p53 positive
- t(11;14) positive
- CD4 positive
- CLDN18.2 positive
- JAK2 positive
- MSI-H negative
- RAD51D positive
- SMN1 positive
- BARD1 positive
- BRCA negative
- CD19 negative
- CD33 positive
- CFTR positive
- Ex19del positive
- FLT3 negative
- HBsAg negative
- HBsAg positive
- HPV16 positive
- NF2 positive
- del(17p) positive
- pMMR positive
- ASXL1 positive
- BAP1 positive
- CD20 negative
- CD3 positive
- COL7A1 positive
- Complex karyotype positive
- HBV DNA positive
- HBcAb positive
- HR negative
- HRAS positive
- HRD positive
- KMT2A positive
- Ki-67 positive
- MDM2 positive
- MSS negative
- NBN positive
- RAF positive
- RF positive
- RUNX1 positive
- TMB positive
- ABCA4 positive
- APC positive
- ATR positive
- Anti-Smith positive
- BCR-ABL positive
- CD4 count positive
- CD8 positive
- CHEK1 positive
- DLL3 positive
- EBV positive
- EZH2 positive
- FANCL positive
- FGFR3 positive
- FMR1 positive
- GRN positive
- HBcAb negative
- Ki67 positive
- MRE11 positive
- MSH6 negative
- PMS2 negative
- PTEN negative
- SF3B1 positive
- SMARCB1 positive
- SMN2 positive
- SRSF2 positive
- TROP2 positive
- TTR positive
- U2AF1 positive
- ZRSR2 positive
- anti-Sm positive
- t(11;14)(q13;q32) positive
- AKT1 positive
- AR positive
- BCOR positive
- CCND1 negative
- CDK4 positive
- DMD positive
- EPCAM positive
- FANCD2 positive
- FGFR1 positive
- FRα positive
- GPC3 positive
- HbSC positive
- HbSβ0-thalassemia positive
- IA-2A positive
- ICA positive
- MECP2 positive
- MLH1 negative
- MSH2 negative
- NPM1 positive
- PDGFRA positive
- PIK3CA negative
- Ph positive
- Philadelphia chromosome negative
- RAD54L positive
- RB positive
- SMARCA4 positive
- SMARCB1 negative
- STK11 positive
- T790M positive
- Gleason Score 10
- Gleason Score 6
- Gleason Score 7
- Gleason Score 8
- Gleason Score 9
- Grade 1
- Grade 2
- Grade 3
- Grade 4
- Stage IV
- Stage III
- Stage II
- Stage I
- 1 Prior Chemotherapy Regimen for Metastatic Disease
- 1927nm Fractional Thulium Laser Treatment
- 2 Episodes of Recurrent Clostridium Difficile Infection
- 2 or More Previous Chemotherapies
- 30-day washout period after Erythropoietin-Stimulating Agent or IV Iron
- ALK TKI Therapy
- ARD-101
- Abrocitinib
- Activating EGFR mutation [exon 19 deletion or exon 21 (L858R) substitution mutation]
- Active Treatment for Cutaneous Squamous Cell Carcinoma
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
11761 trials
Kingman, KS (<20 mi)
Waitlist
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial will test a combination of drugs to see if they are effective in reducing the chance of cancer recurrence or developing new cancers.
Efficacy & Safety Awards
Pivotal Trial
Kingman, KS (<20 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing giredestrant, a medication given after initial treatment to prevent breast cancer from returning. It focuses on patients with a specific type of early-stage breast cancer that is hormone-driven and at higher risk of recurrence. Giredestrant works by blocking the hormone estrogen from helping cancer cells grow. Giredestrant has shown promise in previous studies.
Efficacy & Safety Awards
Pivotal Trial
No Placebo-Only Group
Kingman, KS (<20 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a 4-drug combo vs. a 3-drug combo to see if the former is more effective in shrinking cancer or preventing its return.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing if vitamin D3 along with regular cancer drugs and another drug that helps the immune system can better treat colorectal cancer that has spread. Vitamin D3 may help the body use essential minerals, making the cancer drugs more effective. Vitamin D3 has been shown to slow down cancer cell growth and help them mature, and it has been effective in reducing intestinal tumors in animal studies.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is comparing radiation therapy alone to radiation therapy with lymph node dissection in treating breast cancer patients who have already had chemotherapy and surgery.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial tests how well nivolumab works in treating patients with anal cancer after they've received other treatments. Nivolumab may help the body's immune system attack the cancer, and may prevent tumor cells from growing and spreading.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing nivolumab with or without ipilimumab to see if it can treat patients with squamous cell lung cancer that has come back after previous treatment.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
Get notified when new Non-Small Cell Lung Cancer trials are postedWe'll send you an email whenever new trials are posted
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial studies how well nivolumab works in treating patients with non-small cell lung cancer. Nivolumab is an immunotherapy drug that helps the immune system attack cancer cells. The goal is to see if it can prevent the cancer from coming back. Nivolumab has shown efficacy in treating various malignancies, including non-small cell lung cancer.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Kingman, KS (<20 mi)
Waitlist
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is studying whether adding ibrutinib to chemotherapy before and after stem cell transplant helps the transplant work better in patients with relapsed or refractory diffuse large B-cell lymphoma.
Efficacy & Safety Awards
Pivotal Trial
Kingman, KS (<20 mi)
Waitlist
Phase 2 & 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is studying afatinib dimaleate with or without cetuximab to treat patients with non-small cell lung cancer that has EGFR mutations.
Efficacy & Safety Awards
No Placebo-Only Group
Kingman, KS (<20 mi)
Waitlist
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial compares erlotinib hydrochloride to observation in treating patients with resected stage IB-IIIA non-small cell lung cancer. Erlotinib hydrochloride may stop tumor cell growth by blocking enzymes needed for cell growth.
Efficacy & Safety Awards
Pivotal Trial
Kingman, KS (<20 mi)
Waitlist
Phase 2 & 3
0 Criteria Met
Eligibility Criteria
Kingman, KS (<20 mi)
Waitlist
Phase 31 Award
0 Criteria Met
Eligibility Criteria
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is studying ibrutinib and rituximab compared to fludarabine phosphate, cyclophosphamide, and rituximab to see which works better in treating patients with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Efficacy & Safety Awards
Pivotal Trial
No Placebo-Only Group
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a new chemotherapy treatment for leukemia that includes an immunotherapy drug.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Kingman, KS (<20 mi)
Waitlist
Phase 34 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is studying a combination of drugs given with or without hormone therapy to see how well they work in treating patients with hormone receptor-positive, HER2-positive breast cancer.
Efficacy & Safety Awards
Pivotal Trial
Approved for 20 Other Conditions
All Individual Drugs Already Approved
No Placebo-Only Group
Get notified when new CLL trials are postedWe'll send you an email whenever new trials are posted
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing rituximab with bendamustine hydrochloride or ibrutinib compared to ibrutinib alone to see how well they work in treating patients with previously untreated chronic lymphocytic leukemia.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Kingman, KS (<20 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is studying two different combinations of drugs to treat patients with newly diagnosed multiple myeloma.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
1
2
3
…50